Introduction
Hepatitis C virus (HCV), a blood-borne virus responsible for inflammation, fibrosis, and cirrhosis of the liver, was first documented in 1989. 1 It plagues nearly 200 million people worldwide out of which it is estimated that 16% of individuals develop compensated cirrhosis over a 20-year timeframe. 2 Most patients with HCV have acquired the virus from either injection drug use or from nosocomial exposure (blood transfusions to hemophiliacs, infected health care workers) where strict blood screening guidelines were not adhered to. 3 HCV can be transmitted from one partner to another in heterosexual and homosexual couples, but the rate of transmission is higher in men who have sex with men, especially those men who have unprotected anal intercourse and have HIV. 4 Transmission of HCV can be prevented by avoiding sharing of needles, tattooing done with strict sterilization techniques, condoms for men who have sex with men, and avoiding sharing toothbrushes and razors.
Acute HCV presents as jaundice in about 25% of patients. Some patients will present with nonspecific fatigue, malaise, or arthralgia. Over several decades, 20%-30% 5 of the HCV population will develop compensated cirrhosis, which can progress to life-threatening decompensated cirrhosis or hepatocellular carcinoma (HCC), obviating the need for liver transplantation for preventing further complications from cirrhosis. Extrahepatic manifestations are often associated with chronic HCV infection and include cryoglobulinemia, porphyria cutanea tarda, membranoproliferative glomerulonephritis, Sjogren's syndrome, idiopathic thrombocytopenic purpura, and Screening for HCV should be done by primary care physicians, to prevent further transmission of the infection, as the acute and chronic phases for HCV are asymptomatic. Screening has been shown to be cost-effective. 8 Worldwide, out of 6 HCV genotypes, type 1 (specifically subtype 1a) is the most common. Genotypes 1-3 are prevalent throughout the US, Japan, and Europe, while genotypes 4-6 cause infection in North Africa, South Africa, and Southeast Asia, respectively. 9 Most genotypes have similar liver disease manifestations, with the exception of genotype 3, which does cause hepatic steatosis. 10 Historically, treatment regimens focused upon pegylated-interferon (Peg-IFN) 11 and later a combination with ribavirin, 12 but at present, the treatment available for hepatitis C targets HCV proteins. However, sustained virologic response (SVR) rates have proved problematic and inconsistent across genotypes with the traditional therapy, 12, 13 especially those involving hard-to-cure genotype 3 and/or cirrhosis. More often than not, patients developed adverse effects, including neuropsychiatric symptoms, flu-like syndromes, gastrointestinal upsets, and insomnia. 14 The breakthrough of direct-acting antivirals (DAAs) in 2011 provided a window of opportunity to substantially elevate SVR rates across all genotypes and subtypes, regardless of treatment experience and cirrhotic factors. The DAAs had an improved safety profile, fewer side effects, better tolerability, and shortened treatment duration with prolonged SVR. The driving force behind DAAs was the identification and targeting of the nonstructural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B) involved in the replication of the HCV genome. 15 As such, three main drug classes emerged: NS5A inhibitors, NS5B polymerase inhibitors (PIs), and NS3/4A protease inhibitors.
2 While first-generation DAAs were approved in joint usage with Peg-IFN and ribavirin, the current treatment regimens have moved away from Peg-IFN. At the forefront of these treatments lies the potent fixed drug combination of sofosbuvir, an NS5B PI, and velpatasvir, an NS5A inhibitor (Epclusa, Gilead Sciences, Foster City, CA, USA). In the ASTRAL-1 trial, once-daily sofosbuvir 400 mg/velpatasvir 100 mg given for 12 weeks was reported to have 99% efficacy across genotypes 1-6 in both treatmentnaive and experienced patients. Two percent of patients out of the 624 treated reported serious adverse effects pertaining to the administered medication. 16 In this review, we discuss the safety, efficacy, and tolerability of the sofosbuvir and velpatasvir pan-genotypic treatment combination.
NS protein inhibitors
As a second-generation NS5A inhibitor, it is widely believed that velpatasvir inhibits hepatitis C viral replication through acting on the crucial "membranous web" that facilitates RNA replication. 17 Velpatasvir is highly bound to plasma protein and undergoes hepatic excretion where it is metabolized by the cytochrome P450 enzyme within the liver. 18 Sofosbuvir is a uridine nucleoside analog inhibitor that targets RNA polymerase, thereby preventing the binding and incorporation of nucleoside triphosphates into mRNA. 19 Extensively metabolized in the liver, sofosbuvir undergoes dephosphorylation into its inactive form, GS-331007. Unlike velpatasvir, sofosbuvir is roughly 60% bound to plasma proteins. Moreover, the greater portion of sofosbuvir is renally excreted. 
Pan-genotypic
In the first of several ASTRAL studies, Feld et al 16 conducted a phase 3, double-blind, placebo-controlled 12-week study involving 624 chronic HCV patients from across the globe representing genotypes 1, 2, 4, 5, and 6. Patients were randomly assigned to the treatment group (a once-daily combination tablet of 400 mg sofosbuvir and 100 mg velpatasvir) or a placebo. At 12 weeks posttherapy, HCV RNA levels were measured to assess treatment efficacy as defined by an SVR-12 rate above 85%. Profiles of patients assigned to the treatment group included compensated cirrhosis (19%), prior treatment experience (32%), which primarily included a Peg-IFN therapy (89%), and a mean age of 54 years. Feld et al 16 reported significantly high SVR rates across all patient populations, whether treatment-naïve or experienced. While the patients assigned to the placebo group elicited no SVR, those assigned to the joint sofosbuvir/velpatasvir therapy had a remarkable 99% SVR. The drug combination was effective in all the HCV genotypes, with SVR rates of 100% among genotypes 2, 4, and 6, 99% among genotype 1b, 98% among genotype 1a, and 97% among genotype 5. 20 Moreover, SVR rates remained high irrespective of whether the patients had cirrhosis and whether they had received previous therapy. 16 Though the primary aim was to assess efficacy, treatment safety was documented through rate of adverse effects and patient-reported outcomes. Only 2 patients receiving treatment, both of whom were infected with genotype 1, had a virologic failure, while roughly 2% of all patients had serious adverse side effects. Furthermore, sofosbuvir/velpatasvir treatment did not increase susceptibility to adverse health events. 20 To better understand the health-related quality of life, impact on fatigue, and work productivity following Drug Design, Development and Therapy 2017:11 submit your manuscript | www.dovepress.com
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Sofosbuvir/velpatasvir for HCv treatment HCV therapy, Younossi et al 21 periodically collected self-administered questionnaires from patients during and after the study. The questionnaires represented a wide spectrum of physiological and psychological domains. A statistically significant improvement in general health, emotional well-being, activity/energy, anxiety, and physical functioning was noted as the study progressed. 21 By completion of therapy, follow-up questionnaires at 24 weeks after treatment cessation reported increase in the same domains with additional improvements in bodily pain, social functioning, mental health, fatigue, and attendance at work. Patients in the placebo arm did not report improvements in the quality of life by completion of therapy.
These results lent credence to the superior efficacy and safety of the combination sofosbuvir/velpatasvir therapy for HCV patients with and without cirrhosis.
Difficult-to-cure populations
In order to address potentially difficult-to-cure populations, Foster et al, 22 along with ASTRAL-2 and ASTRAL-3 investigators, conducted two randomized, phase 3, open-label studies. They enrolled genotype 2 or 3 patients with and without treatment experience and with and without cirrhosis. 22 Patients were separated based on genotype and randomly assigned to two treatment groups: a once-daily combination tablet of 400 mg sofosbuvir and 100 mg velpatasvir for 12 weeks or 400 mg of sofosbuvir plus weight-based ribavirin for either 12 or 24 weeks. Patients with genotype 2 in the sofosbuvir/velpatasvir combination tablet treatment arm achieved a 99% SVR. Sofosbuvir plus weight-based ribavirin combination for 12 weeks is an alternative regimen for genotype 2 HCV patients without cirrhosis with an achievement of SVR in 94% of cases. This same regimen can be applied to genotype 3 HCV patients with 80% SVR achievement and similar tolerability despite extended treatment duration of 24 weeks in this group of patients. 22 In the ASTRAL-3 trial, genotype 3 treatment-naive and experienced patients were separated into two treatment arms, with one group receiving 12 weeks of daily sofosbuvir/velpatasvir and the other group receiving 24 weeks of sofosbuvir plus weightbased ribavirin. In the sofosbuvir/velpatasvir arm, 95% of genotype 3 patients achieved SVR (95% CI, 92%-98%) compared with 80% of SVR achievement (CI, 75%-85%) in the sofosbuvir and weight-based ribavirin group.
Efficacy in cirrhotic patients was also evaluated with cirrhotics in the sofosbuvir/velpatasvir group, and they achieved a 91% SVR compared with a 66% SVR in the sofosbuvir/ribavirin group. 22 Adverse health events (Table 1) were more likely to occur in the sofosbuvir/ribavirin group than in the sofosbuvir/velpatasvir group (71.3% vs 52.3%). At present, there is no dosage adjustment required for sofosbuvir in patients with chronic kidney disease or creatinine clearance less than 30 mL/min. As was the case with the ASTRAL-1 study, Younossi et al 23 documented patientreported outcomes during and after therapy. Four weeks into the treatment, statistically and clinically significant improvements were observed in many of the prodomains among sofosbuvir/velpatasvir treated patients, including physical and emotional well-being, bodily pain, and general health. 23 Sofosbuvir/ribavirin therapy yielded varying results, with patients reporting increased body aches, poorer emotional health, and well-being. Patients also reported impaired social functioning and physical well-being, decreased below the baseline level. The immediate benefits provided by sofosbuvir/velpatasvir to whole-body health, especially difficult-to-cure genotype 3 patients, was superior to the sofosbuvir plus weight-based ribavirin therapy.
Decompensated cirrhosis
The annual progression rate of compensated cirrhosis to decompensated cirrhosis is estimated at 3%-6%. 2 The prevalence of decompensated cirrhosis is expected to rise until 2030, which will most likely result in an increase in the number of liver transplantations. 24 Treatment with sofosbuvir/velpatasvir 16 Foster et al, 22 and Younossi et al. 25 enrolled Child-Turcotte-Pugh (CTP) class B patients with genotypes 1, 2, 3, 4, and 6. Similar to the design of the ASTRAL-2 and ASTRAL-3 study, patients were randomly assigned to 400 mg sofosbuvir-100 mg velpatasvir, or 400 mg sofosbuvir/velpatasvir plus weight-based ribavirin. Of the 267 enrolled, slightly over half were treatment-experienced, and none had been treated previously with an NS5A or NS5B inhibitor. Of the patients who received sofosbuvir/velpatasvir, 83% and 86% achieved an SVR following 12 and 24 weeks of treatment, respectively. 25 Interestingly, the addition of ribavirin to the sofosbuvir/velpatasvir therapy yielded a much higher SVR rate, 94%. However, these differences in SVR rates were not statistically significant. The ASTRAL-3 studies did not show superior results of sofosbuvir/ribavirin treatment; the potential benefit of adding ribavirin to the Food and Drugs Administration-approved combination tablet of sofosbuvir/velpatasvir must be considered. On its own, sofosbuvir/velpatasvir for either duration (12, 24 weeks) had a 50% SVR rate among genotype 3 patients with decompensated cirrhosis, but with the addition of weight-based ribavirin, the SVR rate rose to 85%. 25 The DAAs improved liver function tests in the treated patient population. From an average baseline CTP score of 8, 47% of patients had improved at least 1 point in their CTP score, while 42% remained stable. 25 Feld and Zeuzem 20 and Foster et al, 22 in their safety results data, noted that decompensated cirrhotic patients were more susceptible to serious adverse health events. Patients treated with sofosbuvir/velpatasvir for 12 weeks or 24 weeks or for 12 weeks with ribavirin experienced serious adverse health events approximately 20% of the times. Similar to the other ASTRAL studies, fatigue and nausea were common adverse health events.
Genotype 7
In an addendum to the ASTRAL-1 investigation, a missequenced patient was later determined to have HCV genotype 7 following treatment with sofosbuvir/ vel patasvir. Originating from the Democratic Republic of Congo, genotype 7 has only been documented in a few individuals. 26, 27 Nonetheless, this patient achieved a SVR, once more highlighting the pan-genotypic ability of the potent combination. 
Drug-drug interactions
Potential drug-drug interactions between sofosbuvir and velpatasvir were evaluated in an open-label study. Eighteen non-HCV, healthy individuals were enrolled, and there were no clinically significant drug-drug interactions reported in this study by Mogalian et al. 28 When administering sofosbuvir or sofosbuvir-containing regimens, patients should be cautioned to avoid rifampin, St John's wort, or tipranavir because these agents decrease the efficacy of sofosbuvir by decreasing circulating drug levels of sofosbuvir (Table 2) . Velpatasvir can have decreased absorption if the patient is on concomitant antacids and acid-reducing medications. Patients should be asked to report all medications they are currently on and if they are going to start on any additional medications including over-the-counter medications or herbal supplements. 
HCV relapse
HCV relapse on sofosbuvir is usually secondary to reexposure to the virus after achieving SVR. Relapses, after using sofosbuvir for therapy, are unlikely to have a virus with resistant variants. Therefore, sofosbuvir can be successfully used to re-treat the same individual who has previously received treatment with sofosbuvir in combination with another alternate antiviral. 29 In relapsed genotype 3 patients, there was an emergence of Y93H baseline variant; therefore, it may be prudent to add weight-based ribavirin to this group with the combination therapy of sofosbuvir and velpatasvir. 30 
Conclusion
The introduction of DAAs to selectively target the HCV replication process has yielded a plethora of scientific research, with promising results at each end. Thus far, the potent combination of sofosbuvir, an NS5B PI, and velpatasvir, an NS5A inhibitor, has shown .94% SVR rates among all major HCV genotypes, including the difficultto-cure genotypic, cirrhotic, and treatment-experienced populations ( Table 3 ). The virologic cure is a possibility with this regimen as SVR rates have been reported at or above 95%. In addition to improvements in general health, emotional and mental well-being and social productivity throughout therapy and posttherapy in a sizeable number of patients illustrate the efficacy of the combination treatment. Currently, pretreatment genotype testing and stage of liver disease fibrosis determine which patients will receive therapy for HCV by the insurance companies. 31 The pan-genotypic success achieved with sofosbuvir/velpatasvir makes therapy simple, safe, and curative, but access to therapy is limited by cost. Once therapy is accessible to all patients, this will decrease health care disease burden with a resultant decrease in morbidity and mortality, and then patients can be cured from the HCV virus without having to undergo pregenotype testing.
Further trials are still needed with the DAAs for hepatitis C to be able to be used in complex patient populations with HIV, diabetes mellitus, or cardiovascular diseases and further prolong the SVR.
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